1. Home
  2. Analysis
  3. Pravachol
  4. Opdivo

Pravachol and Opdivo drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pravachol (pravastatin sodium) and Opdivo (nivolumab). Common drug interactions include erythema among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Pravachol and Opdivo. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Pravachol?

Pravachol has active ingredients of pravastatin sodium. It is often used in high blood cholesterol. eHealthMe is studying from 24,382 Pravachol users. Check the latest studies of Pravachol.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

On Jul, 28, 2026

34 people who take Pravachol and Opdivo together, and have interactions are studied.

Pravachol and Opdivo drug interactions.

What are the common drug interactions of Pravachol and Opdivo, by gender? *:

female:

  1. Erythema (redness of the skin)
  2. Ingrowing nail
  3. Weight decreased
  4. Diarrhoea
  5. Eye irritation
  6. Hordeolum (small collection of pus (abscess) on the eyelid)
  7. Hypertension (high blood pressure)
  8. Malignant neoplasm progression (cancer tumour came back)
  9. Pain
  10. Thyroid disorder (thyroid diseases)

male:

  1. Death
  2. Adverse event
  3. Drug ineffective
  4. Thermal burn (burn by heat)
  5. Malignant neoplasm progression (cancer tumour came back)
  6. Pneumonia

What are the common drug interactions of Pravachol and Opdivo, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Death

60+:

  1. Fatigue (feeling of tiredness)
  2. Asthenia (weakness)
  3. Eye irritation
  4. Hordeolum (small collection of pus (abscess) on the eyelid)
  5. Hypertension (high blood pressure)
  6. Malignant neoplasm progression (cancer tumour came back)
  7. Pain
  8. Thyroid disorder (thyroid diseases)
  9. Wound
  10. Constipation

What are the existing conditions these people have? *

  1. High Blood Pressure: 6 people, 17.65%
  2. Renal Cell Carcinoma (a kidney cancer): 4 people, 11.76%
  3. Oesophageal Carcinoma (cancer tumour of oesophagus): 4 people, 11.76%
  4. Malignant Melanoma (skin cancer rises from melancytes): 4 people, 11.76%
  5. Lung Neoplasm Malignant (cancer tumour of lung): 4 people, 11.76%
  6. Vulval Cancer: 2 people, 5.88%
  7. Thyroid Diseases: 2 people, 5.88%
  8. Osteopenia (a condition where bone mineral density is lower than normal): 2 people, 5.88%
  9. Neoplasm Malignant (cancer tumour): 2 people, 5.88%
  10. Nausea (feeling of having an urge to vomit): 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Pravachol and Opdivo?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Pravachol and Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Pravachol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pravachol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Opdivo and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on pravastatin sodium and nivolumab (the active ingredients of Pravachol and Opdivo, respectively), and Pravachol and Opdivo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.